Effect of omega-3 fatty acids on cardiovascular events in high-risk patients with hypertriglyceridemia in Japan: a 3-year post-marketing surveillance study (OCEAN3 survey)

References

• Kinoshita M, Yokote K, Arai H, et al. Japan Atherosclerosis Society (JAS) guidelines for prevention of atherosclerotic cardiovascular diseases 2017. J Atheroscler Thromb. 2018 Sep 1;25(9):846–984.
   PubMed Web of Science ®Google Scholar
• Visseren FLJ, Mach F, Smulders YM, et al. 2021 ESC guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J. 2021 Sep 7;42(34):3227–3337.
   PubMed Web of Science ®Google Scholar
• Averna M, Stroes E. How to assess and manage cardiovascular risk associated with lipid alterations beyond LDL. Atheroscler Suppl. 2017 Apr;26:16–24.
   PubMed Web of Science ®Google Scholar
• Sampson UK, Fazio S, Linton MF. Residual cardiovascular risk despite optimal LDL cholesterol reduction with statins: the evidence, etiology, and therapeutic challenges. Curr Atheroscler Rep. 2012 Feb;14(1):1–10.
   PubMed Web of Science ®Google Scholar
• Klempfner R, Erez A, Sagit BZ, et al. Elevated triglyceride level is independently associated with increased all-cause mortality in patients with established coronary heart disease: twenty-two–year follow-up of the Bezafibrate Infarction Prevention study and registry. Circ Cardiovasc Qual Outcomes. 2016 Mar;9(2):100–108.
   PubMed Web of Science ®Google Scholar
• Iso H, Imano H, Yamagishi K, et al. Fasting and non-fasting triglycerides and risk of ischemic cardiovascular disease in Japanese men and women: the Circulatory Risk in Communities Study (CIRCS). Atherosclerosis. 2014 Nov;237(1):361–368.
   PubMed Web of Science ®Google Scholar
• Okamura T, Kokubo Y, Watanabe M, et al. A revised definition of the metabolic syndrome predicts coronary artery disease and ischemic stroke after adjusting for low density lipoprotein cholesterol in a 13-year cohort study of Japanese: the Suita study. Atherosclerosis. 2011 Jul;217(1):201–206.
   PubMed Web of Science ®Google Scholar
• Noda H, Iso H, Saito I, et al. The impact of the metabolic syndrome and its components on the incidence of ischemic heart disease and stroke: the Japan public health center-based study. Hypertens Res. 2009 Apr;32(4):289–298.
   PubMed Web of Science ®Google Scholar
• Nichols GA, Philip S, Reynolds K, et al. Increased cardiovascular risk in hypertriglyceridemic patients with statin-controlled LDL cholesterol. J Clin Endocrinol Metab. 2018 Aug 1;103(8):3019–3027.
   PubMed Web of Science ®Google Scholar
• Backes J, Anzalone D, Hilleman D, et al. The clinical relevance of omega-3 fatty acids in the management of hypertriglyceridemia. Lipids Health Dis. 2016 Jul 22;15(1):118.
   PubMed Web of Science ®Google Scholar
• Skulas-Ray AC, Wilson PWF, Harris WS, et al. Omega-3 fatty acids for the management of hypertriglyceridemia: a science advisory from the American Heart Association. Circulation. 2019 Sep 17;140(12):e673–e691.
   PubMed Web of Science ®Google Scholar
• Watanabe Y, Tatsuno I. Omega-3 polyunsaturated fatty acids for cardiovascular diseases: present, past and future. Expert Rev Clin Pharmacol. 2017 Aug;10(8):865–873.
   PubMed Web of Science ®Google Scholar
• Albert CM, Cook NR, Pester J, et al. Effect of marine omega-3 fatty acid and vitamin D supplementation on incident atrial fibrillation: a randomized clinical trial. JAMA. 2021 Mar 16;325(11):1061–1073.
   PubMed Web of Science ®Google Scholar
• Bhatt DL, Budoff MJ, Mason RP. A revolution in omega-3 fatty acid research. J Am Coll Cardiol. 2020 Nov 3;76(18):2098–2101.
   PubMed Web of Science ®Google Scholar
• Pradhan A, Bhandari M, Vishwakarma P, et al. Triglycerides and cardiovascular outcomes—can we REDUCE-IT? Int J Angiol. 2020 Mar;29(1):2–11.
   PubMed Web of Science ®Google Scholar
• Watanabe Y, Tatsuno I. Prevention of cardiovascular events with omega-3 polyunsaturated fatty acids and the mechanism involved. J Atheroscler Thromb. 2020 Mar 1;27(3):183–198.
   PubMed Web of Science ®Google Scholar
• Tatsuno I, Saito Y, Kudou K, et al. Efficacy and safety of TAK-085 compared with eicosapentaenoic acid in Japanese subjects with hypertriglyceridemia undergoing lifestyle modification: the omega-3 fatty acids randomized double-blind (ORD) study. J Clin Lipidol. 2013 May-Jun;7(3):199–207.
   PubMed Web of Science ®Google Scholar
• Tatsuno I, Saito Y, Kudou K, et al. Long-term safety and efficacy of TAK-085 in Japanese subjects with hypertriglyceridemia undergoing lifestyle modification: the omega-3 fatty acids randomized long-term (ORL) study. J Clin Lipidol. 2013 Nov-Dec;7(6):615–625.
   PubMed Web of Science ®Google Scholar
• Yokoyama M, Origasa H, Matsuzaki M, et al. Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomised open-label, blinded endpoint analysis. Lancet. 2007 Mar 31;369(9567):1090–1098.
   PubMed Web of Science ®Google Scholar
• Austin PC. The use of propensity score methods with survival or time-to-event outcomes: reporting measures of effect similar to those used in randomized experiments. Stat Med. 2014 Mar 30;33(7):1242–1258.
   PubMed Web of Science ®Google Scholar
• Keaney JF Jr., Rosen CJ. VITAL signs for dietary supplementation to prevent cancer and heart disease. N Engl J Med. 2019 Jan 3;380(1):91–93.
   PubMed Web of Science ®Google Scholar
• Elagizi A, Lavie CJ, O’Keefe E, et al. An update on omega-3 polyunsaturated fatty acids and cardiovascular health. Nutrients. 2021 Jan 12;13(1):204.
   PubMed Web of Science ®Google Scholar
• Matsuo N, Miyoshi T, Takaishi A, et al. High plasma docosahexaenoic acid associated to better prognoses of patients with acute decompensated heart failure with preserved ejection fraction. Nutrients. 2021 Jan 26;13(2):371.
   PubMed Web of Science ®Google Scholar
• Tavazzi L, Maggioni AP, Marchioli R, et al. Effect of n-3 polyunsaturated fatty acids in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial. Lancet. 2008 Oct 4;372(9645):1223–1230.
   PubMed Web of Science ®Google Scholar
• Toko H, Morita H, Katakura M, et al. Omega-3 fatty acid prevents the development of heart failure by changing fatty acid composition in the heart. Sci Rep. 2020 Sep 23;10(1):15553.
   PubMed Web of Science ®Google Scholar
• Marston NA, Giugliano RP, Im K, et al. Association between triglyceride lowering and reduction of cardiovascular risk across multiple lipid-lowering therapeutic classes: a systematic review and meta-regression analysis of randomized controlled trials. Circulation. 2019 Oct 15;140(16):1308–1317.
   PubMed Web of Science ®Google Scholar
• Visioli F, Poli A. Fatty acids and cardiovascular risk. evidence, lack of evidence, and diligence. Nutrients. 2020 Dec 9;12(12):3782.
   PubMed Web of Science ®Google Scholar
• Marchioli R. Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI-Prevenzione trial. Gruppo Italiano per lo Studio della Sopravvivenza nell’Infarto miocardico. Lancet. 1999 Aug 7;354(9177):447–455.
   PubMed Web of Science ®Google Scholar
• Boden WE, Baum S, Toth PP, et al. Impact of expanded FDA indication for icosapent ethyl on enhanced cardiovascular residual risk reduction. Future Cardiol. 2021 Jan;17(1):155–174.
   PubMed Web of Science ®Google Scholar
• Kalstad AA, Myhre PL, Laake K, et al. Effects of n-3 fatty acid supplements in elderly patients after myocardial infarction: a randomized, controlled trial. Circulation. 2021 Feb 9;143(6):528–539.
   PubMed Web of Science ®Google Scholar
• Nicholls SJ, Lincoff AM, Garcia M, et al. Effect of high-dose omega-3 fatty acids vs corn oil on major adverse cardiovascular events in patients at high cardiovascular risk: the STRENGTH randomized clinical trial. JAMA. 2020 Dec 8;324(22):2268–2280.
   PubMed Web of Science ®Google Scholar
• Bernasconi AA, Wiest MM, Lavie CJ, et al. Effect of omega-3 dosage on cardiovascular outcomes: an updated meta-analysis and meta-regression of interventional trials. Mayo Clin Proc. 2021 Feb;96(2):304–313.
   PubMed Web of Science ®Google Scholar
• Farukhi ZM, Mora S, Manson JE. Marine omega-3 fatty acids and cardiovascular disease prevention: seeking clearer water. Mayo Clin Proc. 2021 Feb;96(2):277–279.
   PubMed Web of Science ®Google Scholar
• Park KY, Park HK, Hwang HS. Omega-3 fatty acids effect on major cardiovascular events in patients at high cardiovascular risk. JAMA. 2021 Apr 6;325(13):1334.
   PubMedGoogle Scholar
• Manson JE, Cook NR, Lee IM, et al. Marine n-3 fatty acids and prevention of cardiovascular disease and cancer. N Engl J Med. 2019 Jan 3;380(1):23–32.
   PubMed Web of Science ®Google Scholar
• Gibson R, Lau CE, Loo RL, et al. The association of fish consumption and its urinary metabolites with cardiovascular risk factors: the International Study of Macro-/Micronutrients and Blood Pressure (INTERMAP). Am J Clin Nutr. 2020 Feb 1;111(2):280–290.
   PubMed Web of Science ®Google Scholar
• Sekikawa A, Curb JD, Ueshima H, et al. Marine-derived n-3 fatty acids and atherosclerosis in Japanese, Japanese-American, and white men: a cross-sectional study. J Am Coll Cardiol. 2008 Aug 5;52(6):417–424.
   PubMed Web of Science ®Google Scholar
• Ueshima H, Okayama A, Saitoh S, et al. Differences in cardiovascular disease risk factors between Japanese in Japan and Japanese-Americans in Hawaii: the INTERLIPID study. J Hum Hypertens. 2003 Sep;17(9):631–639.
   PubMed Web of Science ®Google Scholar
• Bhatt DL, Steg PG, Miller M, et al. Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia. N Engl J Med. 2019 Jan 3;380(1):11–22.
   PubMed Web of Science ®Google Scholar
• Hu Y, Hu FB, Manson JE. Marine omega-3 supplementation and cardiovascular disease: an updated meta-analysis of 13 randomized controlled trials involving 127 477 participants. J Am Heart Assoc. 2019 Oct;8(19):e013543.
   PubMed Web of Science ®Google Scholar
• Budoff MJ, Bhatt DL, Kinninger A, et al. Effect of icosapent ethyl on progression of coronary atherosclerosis in patients with elevated triglycerides on statin therapy: final results of the EVAPORATE trial. Eur Heart J. 2020 Oct 21;41(40):3925–3932.
   PubMed Web of Science ®Google Scholar
• Ruscica M, Ferri N, Santos RD, et al. Lipid lowering drugs: present status and future developments. Curr Atheroscler Rep. 2021 Mar 10;23(5):17.
   PubMed Web of Science ®Google Scholar
• Nissen SE, Lincoff AM, Wolski K, et al. Association between achieved ω-3 fatty acid levels and major adverse cardiovascular outcomes in patients with high cardiovascular risk: a secondary analysis of the STRENGTH trial. JAMA Cardiol. 2021 May 16;6(8):1–8.
   PubMed Web of Science ®Google Scholar
• Olshansky B, Bhatt DL, Chung MK. Omega-3 fatty acids effect on major cardiovascular events in patients at high cardiovascular risk. JAMA. 2021 Apr 6;325(13):1332–1333.
   PubMedGoogle Scholar
• Volpe M, Patrono C. The REDUCE-IT verdict on eicosapentaenoic acid and cardiovascular outcome challenged with STRENGTH. Eur Heart J. 2021 Feb 1;42(5):370–371.
   PubMed Web of Science ®Google Scholar
• Curfman G. Do omega-3 fatty acids benefit health? JAMA. 2020 Dec 8;324(22):2280–2281.
   PubMed Web of Science ®Google Scholar
• Sharma G, Martin SS, Blumenthal RS. Effects of omega-3 fatty acids on major adverse cardiovascular events: what matters most: the drug, the dose, or the placebo? JAMA. 2020 Dec 8;324(22):2262–2264.
   PubMed Web of Science ®Google Scholar
• Tatsuno I, Kudou K, Kagawa T. Effect of TAK-085 on low-density lipoprotein particle si0ze in patients with hypertriglyceridemia: a double-blind randomized clinical study. Cardiovasc Ther. 2015 Dec;33(6):317–323.
   PubMed Web of Science ®Google Scholar
• Wang Y. Omega-3 fatty acids effect on major cardiovascular events in patients at high cardiovascular risk. JAMA. 2021 Apr 6;325(13):1333.
   PubMedGoogle Scholar